Q. As a trusted leading CRO in Korea, GCCL is making its debut as an official sponsor at BIX 2025 and is also hosting an exclusive networking reception, demonstrating a significant expansion of its engagement.
Notably, as this is the first major external initiative under the new leadership, the participation carries even greater significance. Could you share the strategic direction under the new management structure, as well as the outcomes you hope to achieve through BIX 2025?

A. This year, GCCL has transitioned to a leadership team composed of experts with extensive experience in drug development and clinical trials, strengthening our strategies and execution to further expand our global business. Notably, as one of the very few domestic CROs, we are participating in BIX 2025 as an official sponsor for the first time and even hosting our own networking reception — marking a new leap forward for us.

For GCCL, BIX is more than just an exhibition. It’s a valuable opportunity to engage in deeper networking with global partners and clients, to showcase our technical excellence and operational expertise, and ultimately to strengthen our presence not only in Asia but across the global clinical trial market.

Q. Building on its strong analytical expertise, GCCL provides testing and certification services at a global standard.
Through BIX 2025, are there particular service areas or technological differentiators you would like to highlight to the industry? If there are newly introduced platforms or customer-centric improvements, could you also share those with us?

A. As an analysis-focused CRO, GCCL is the only company in Korea equipped with Biosafety Level 1–3 facilities, offering a true All-In-One Lab Solution that covers every essential stage of clinical trials — from bioanalytical method development to sample logistics, analysis, quality management, and project oversight. With our Central Lab, Bioanalytical Lab, and R&D Lab working in close connection with Project Management and Clinical Sample Management, we deliver fully integrated services for clinical sample analysis.

Backed by extensive experience in multinational clinical trials and partnerships with global pharmaceutical companies, GCCL provides high-quality analytical services built on robust SOPs, a validated LIMS system, and internationally compliant quality frameworks.

At BIX 2025, we will highlight these global-level operational capabilities, showcasing GCCL’s unique strengths as Korea’s leading analytical CRO: data quality, customer-centric service, and proven global project execution.

Q. Within your exhibition booth at BIX 2025, are there any special programs, demonstrations, or distinctive features that Visitors can look forward to experiencing? If you have prepared specific initiatives to engage and interact with Visitors, could you please share those as well?

A. The GCCL booth has been designed not just as a showcase, but as an interactive space where visitors can truly experience our capabilities. One highlight will be the “Virtual Lab Tour,” a touchscreen feature that simulates the workflow, equipment, and environment of our laboratories, allowing visitors to gain an intuitive understanding of GCCL’s infrastructure, service scope, and quality management system. In addition, the booth will focus on two-way engagement — offering live Q&A sessions and business matching opportunities with visitors. Through this, we aim to build stronger technical trust with both domestic and global clinical trial stakeholders.

Q. At the upcoming GCCL Networking Reception, will there be any dedicated presentation sessions or special programs that you could share in advance? We would also like to know what key messages you intend to deliver to the Visitors joining the event.

A. The exclusive reception hosted by GCCL will be presented under the concept of “K-Bio IR Pitching Day organized by GCCL,” designed as an open IR platform that brings together investors and promising biotech companies. Around ten innovative biotech firms will take the stage to deliver live pitches, creating opportunities for meaningful networking with investors and paving the way for potential investment connections.

At GCCL, we believe that “our growth comes from the success of our clients.” With this philosophy, the event goes beyond promoting GCCL alone — it is about fostering opportunities for our partners and driving growth across the entire industry. This reception represents a meaningful step toward the globalization of Korea’s clinical trial sector and the expansion of the broader K-Bio ecosystem.